No changes to the Galenica Group shareholder structure to result from the strategic partnership between Alliance Boots and Walgreens
Tuesday, 19 June 2012, ↓ directly to download
Alliance Boots and Walgreens today announced that they have entered into a strategic partnership designed to create the first global pharmacy-led health and wellbeing enterprise. Alliance Boots’s interest in the Galenica Group does not form part of this transaction. There will therefore be no changes to the Galenica Group shareholder structure as a result of the strategic partnership between Alliance Boots and Walgreens.
_Alliance Boots holds around 25% of the registered shares in the Galenica Group, of which 20% with voting rights and the remainder without voting rights. This share package does not form part of the agreement between Walgreens and Alliance Boots and will continue to be owned by Alliance Boots for the benefit of existing shareholders after the transaction between the two companies has been concluded. There will therefore be no changes to the Galenica Group shareholder structure as a result of the new partnership between Alliance Boots and Walgreens.
_The Galenica Group has maintained a strategic partnership with Alliance Boots since 1999. This partnership is part of an agreement. It is underpinned by the membership of the Galenica Board of Directors of Stefano Pessina, Executive Chairman of the Board of Directors and one of the main shareholders in Alliance Boots, and the membership of the Alliance Boots Board of Directors of Etienne Jornod, Executive Chairman of the Board of Directors of Galenica. There will also be no changes in this regard as a result of the agreement between Alliance Boots and Walgreens.
_Further information on the strategic partnership between Alliance Boots and Walgreens can be found at the following website: www.allianceboots.com.
Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group’s income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).
Thursday, 20 December 2012
Friday, 9 November 2012
Tuesday, 14 August 2012
Thursday, 26 July 2012
Head of Corporate Communications